Pharmaceutical Care for One Case of Multi-target Treatment for Refractory ClassⅣ+ⅤLupus Nephritis
10.6039/j.issn.1001-0408.2015.29.45
- VernacularTitle:1例多靶点方案治疗难治性Ⅳ+Ⅴ型狼疮性肾炎患者的药学监护
- Author:
Juan ZHAO
;
Fang ZENG
- Publication Type:Journal Article
- Keywords:
Multi-target;
Lupus nephritis;
Individualized treatment;
Pulmonary infection;
Blood pressure elevated
- From:
China Pharmacy
2015;(29):4158-4159,4160
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To summarize the method and experience of clinical pharmacist participating in pharmaceutical care for a case of refractory class Ⅳ+Ⅴ lupus nephritis (LN). METHODS:Clinical pharmacists and physicians formulated individualized treatment together,i.e. prednisone 30 mg/d+MMF 0.5 g,q12 h+FK506 1 mg,q12 h;on the fifth day of treatment,the patient suf-fered from ardent fever and increase of blood pressure,and clinical pharmacist suggested using linezolid 0.6 g,ivdrip,q12 h+merope-nem1.0 g,ivdrip,q8 h to control pulmonary infection;using Amlodipine besylate tablet 5 mg,po,qd+one Valsartan hydrochlorothia-zide capsule, po,qd+Arotinolol hydrochlorid tablet 10 mg,po,bid to control blood pressure. RESULTS:Multi-target treatment for re-fractory class Ⅳ+Ⅴ lupus nephritis achieved efficacy:the patient got higher plasma albumin and lower 24 h urine protein quantity af-ter 14 days;the patient suffered from secondary pulmonary infection and high blood pressure;physicians adopted the pharmacist’s suggestion so that pulmonary infection and blood pressure had been controlled. CONCLUSIONS:To ensure the effectiveness and safe-ty of the multi-target treatment,clinical pharmacists should formulate individualized treatment,focus on the possible ADR and provide phamaceutical care in the field of blood pressure monitoring,infection control,etc. when participating in multi-target treatment.
